J INTS BIO Presents Interim Results from the Preclinical Study of ‘JIN-001’ in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance
Hand-out
Press Releases
October 24, 2024

J INTS BIO Presents Interim Results from the Preclinical Study of ‘JIN-001’ in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance

SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- J INTS BIO, a leader in oncology drug development, has revealed interim preclinical results of its second-generation synthetic HSP90 inhibitor, JIN-001, at

bradford

The Bradford Era

Local & Social